CX157

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CX157
CX157 structure.svg
Systematic (IUPAC) name
3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
Clinical data
  • Uncontrolled
Oral
Identifiers
None
PubChem CID 18687754
ChemSpider 13701383 YesY
Chemical data
Formula C14H8F4O4S
348.27 g/mol
 YesY (what is this?)  (verify)

CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2]

See also[edit]

References[edit]

  1. ^ Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Retrieved 2009-06-14. 
  2. ^ Clinical trial number NCT00739908 at ClinicalTrials.gov